Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 912 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically... August 8, 2023 Respuestas a sus preguntas sobre la vacuna contra el COVID-19 March 12, 2021 Reflecting on COVID-19 and the Importance of Providing Information to People... July 21, 2022 DeFi Trial: Smart Design and Impressive Results For the Benefit of... September 10, 2022 Load more HOT NEWS Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... How to Support a Spouse or Partner During Cancer Treatment by... Choosing to act on cancer: Our Manifesto for Cancer Research and...
